CT criteria of the resectability of pankreas carcinoma

Petrovic, Dragana; Prvulović-Bunović, Nataša; Petrović, Predrag

doi:10.5937/medgla2078052p

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Serbia, mandatory immunization against HB for newborn infants born to HBsAg-positive mothers and people at high risk of HBV infection, including healthcare workers (HCWs), started in 1988. In addition, universal mandatory immunization against HBV of all unvaccinated children at the age of 12 (catch-up campaign) and for all newborns was adopted and implemented in 2005 and 2006, respectively [ 13 , 14 ]. The vaccination schedule for newborns is to receive the first dose 24 h after birth; the second dose is administered at the age of one month and the third dose at the age of six months.…”

Section: Introductionmentioning

confidence: 99%

Seroprevalence Study of Anti-HBs Antibodies in the General Population of Vojvodina, Serbia

Rajčević,

Medić,

Patić

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Hepatitis B (HB) is a major global health problem and a potentially life-threatening disease caused by the hepatitis B virus (HBV). Also, it is an important cause of morbidity and mortality worldwide. Thanks to serological surveys, testing hepatitis B surface antibodies (anti-HBs) allows for serological assessments of their prevalence. The presence of anti-HBs, which protects against HBV infection, can be attributed to HB vaccination or natural HBV infection. The aim of our study was to evaluate the prevalence of HB surface antibodies (anti-HBs) as an indicator of collective immunity against HBV in the general population of the Autonomous Province of Vojvodina, Serbia. In addition, to distinguish whether anti-HBs were induced by the vaccine or by infection, the presence of antibodies against the hepatitis B core antigen (anti-HBc) was tested among those who were anti-HBs-positive. Materials and Methods: A total of 3467 residual sera samples, collected according to the specifications of the European Sero-Epidemiology Network 2 (ESEN2) study, from April 2015 to March 2016, were screened for the presence of anti-HBs using a chemiluminescence immunoassay. The difference between categorical variables was tested using the chi-square test. Results: Overall, 1870 (53.9%, 95% CI: 52.3–55.6) participants tested positive for anti-HBs. The median age of the study participants was 17 years (IQR 9–35). The anti-HB seroprevalence decreased with age, ranging from 80.7% (95% CI: 78.9–82.4) in the 1–19-year-old group to 16.4% (95% CI: 12.0–20.9) in the ≥60 years’ age group. A total of 71 (3.8%, 95% CI: 2.9–4.7) serum samples were also anti-HBc-positive. Higher prevalence, but not statistically significant, was noticed in women (4.1%, 95% CI: 2.8–5.4) compared with men (3.5, 95% CI: 2.4–4.8) (p = 0.542). Also, there was a significant difference across the age groups, where those ≥60 years old had a prevalence of 65.9% (95% CI: 51.9–79.9) and the age category of 1–19-year-olds had just 0.2% (95% CI: 0.0–0.4) (p < 0.001). Conclusions: This study provides a comprehensive assessment of the anti-HBs seroprevalence of the general population in Vojvodina and provides an opportunity to better shape the national preventive strategy related to HBV.

show abstract

Section: Introductionmentioning

confidence: 99%